Nevro Corp. said it plans to raise more than $100 million in an initial public offering of stock for its implantable spinal cord stimulation system to treat chronic pain.
Initial Public Offering (IPO)
Vital Therapies prices offering
Second Sight Medical eyes $3m bridge to IPO
Second Sight Medical is looking to bridge the gap to its forthcoming initial public offering with a $3 million loan from iconic chairman Al Mann.
UCLA spinout NeuroSigma seeks $50m in IPO
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout’s noninvasive system to treat drug-resistant epilepsy.
NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for between $13 and $15 each, reserving the symbol NSIG, according to a regulatory filing.
EndoStim targets $36m IPO
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.
Breast implant maker Sientra registers an $86M IPO
California medical device maker Sientra Inc. is looking to hit the public markets with an initial public offering that could raise as much as $86.3 million, according to an SEC filing.
ReWalk Robotics prices IPO at $36M, below range
ReWalk Robotics (NSDQ:RWLK) priced its initial public offering below its forecast range, at $12 per share, grossing some $36.0 million for its exo-skeleton suit.
Mevion Medical files for $69M IPO
IPOs: ReWalk and NeuroSigma prepare to hit the public market
Two medical device makers are preparing initial public offerings for the coming weeks, breaking up a spree of biotech IPOs that have dominated the market.
Ocular Therapeutix IPO reaches $75M with over-allotment
Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.